Which institutions or companies are sponsoring gelatide clinical research?
Executive summary
Available sources do not list any clinical trials or sponsors explicitly named for a product called “gelatide.” Literature and conference materials instead document academic groups, industry suppliers, and gelatin-focused companies involved in preclinical research, materials development, and clinical-trial support services—e.g., academic GelMA (gelatin methacryloyl) work on cartilage/bone scaffolds (PubMed) and market/industry players such as Rousselot, Gelita and PB Leiner mentioned in market reporting [1] [2] [3].
1. No direct “gelatide” clinical sponsors found — what the sources actually cover
A targeted look through the provided results shows studies and reviews about gelatin-based biomaterials (GelMA hydrogels, gelatin scaffolds, gelatin drug‑delivery systems) and industry players in the gelatin supply chain, but none of the documents identify a clinical candidate named “gelatide” or list companies/institutions sponsoring a clinical program for a product with that name; available sources do not mention a “gelatide” sponsor or trial registry entry [1] [2] [4] [3].
2. Academic groups and preclinical GelMA research are prominent
Primary research articles highlighted in PubMed and ScienceDirect describe GelMA and other gelatin derivatives being developed for cartilage and bone tissue engineering, with authors affiliated to university medical colleges and research centers — for example, work on GelMA composites for osteochondral regeneration is tied to clinical medical colleges and research teams rather than a commercial sponsor [1] [2].
3. Reviews trace clinical and preclinical progress but not a “gelatide” sponsor
Comprehensive reviews catalog the development of gelatin-based drug-delivery systems and tissue-engineering scaffolds and summarize 45 preclinical and clinical studies up to 2023, but they discuss gelatin as a platform rather than a branded clinical product; they do not point to an industry sponsor for “gelatide” specifically [4] [5].
4. Industry players supply GMP gelatin and collaborate with research institutes
Market reporting and industry overviews identify commercial gelatin suppliers (Rousselot, Gelita, PB Leiner) and describe collaborations to develop gelatin derivatives for clinical application (e.g., Rousselot–TIBI collaboration and PB Leiner product launches), indicating where translational support and materials for trials are likely sourced even if they are not naming trial sponsors for a specific “gelatide” therapy [3].
5. Clinical-trial ecosystem vendors and CROs are visible in conference materials
Conference sponsor and exhibitor lists (clinical trial supply, outsourcing and patient-partnership events) repeatedly name CROs, logistics firms, lab services, and trial-enablement vendors (Akesa, Labcorp, Signant, Advarra, Florence Healthcare, Care Access, etc.), reflecting the types of organizations that typically enable sponsored trials; these sources show the ecosystem but do not tie any of those service providers to a “gelatide” sponsor [6] [7] [8] [9] [10].
6. What this means for your query — two plausible interpretations
If by “gelatide” you mean a specific branded clinical product, current reporting in the provided dataset contains no evidence of sponsors, registries, or trial listings using that name (not found in current reporting) [1] [4] [3]. If you meant gelatin-derived clinical programs more broadly (GelMA, gelatin scaffolds, gelatin DDS), the sponsors are mainly academic investigators and collaborations with gelatin suppliers and industry partners; the literature and market reports point to universities and gelatin manufacturers driving translational work while trial-enabling services are supplied by CROs and logistics firms [1] [2] [4] [3] [6].
7. Limits of the available reporting and recommended next steps
The sources are strong on materials science, reviews of gelatin platforms, and industry supply-chain partnerships but do not include clinicaltrials.gov entries or press releases naming a “gelatide” sponsor. To resolve whether “gelatide” is a branded candidate with active clinical sponsorship, check clinical trial registries (ClinicalTrials.gov, EU‑CTR), company press releases for startups/dog-bone‑named products, and recent PubMed/industry announcements beyond these materials; the current set does not provide that registry-level confirmation [4] [3] [1].
8. Competing perspectives and hidden agendas to watch
Academic publications emphasize scientific promise and translational potential (motivated by publication and grant funding) while market reports and supplier press note commercial opportunity and product positioning (motivated by sales and investor messaging) — both may overstate clinical readiness. Conference sponsor lists showcase vendors that profit when a program proceeds to clinical stages; none of the supplied materials explicitly links those vendors to a “gelatide” clinical sponsor [6] [7] [9] [10] [3].
If you want, I can run targeted searches of clinical trial registries and corporate press releases (within your allowed sources) to try to locate any trial or sponsor using the exact name “gelatide.”